Entasis Therapeutics develops a portfolio of anti-infective programs aimed at serious drug-resistant bacterial infections. Its pipeline includes ETX2514SUL, ETX0282CPDP, a non-beta-lactam penicillin-binding protein (PBP) inhibitor program, and zoliflodacin. The non-beta-lactam PBP program is in lead optimization and has shown potent in vitro and in vivo activity against multidrug-resistant Gram-negative pathogens including Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae, and Acinetobacter baumannii. Entasis plans to advance the PBP program through Phase 1 clinical trials with support from CARB-X. The company recently received a staged CARB-X award committing initial funding up to $3.8 million and up to an additional $6.3 million upon milestone achievement, for a potential total of $10.1 million. Entasis positions these programs to address the growing global need for new antibiotics active against resistant Gram-negative bacteria. Entasis Therapeutics develops a portfolio of anti-infective products derived from a proprietary discovery and preclinical platform that leverages bacterial genomics, molecular dynamics and structure-based design. Its pipeline includes differentiated programs such as ETX2514SUL (targeting Acinetobacter baumannii), ETX0282CPDP (targeting Enterobacteriaceae) and zoliflodacin (targeting Neisseria gonorrhoeae). The company is focused on advancing programs with improved efficacy and tolerability against drug-resistant, high-mortality Gram-negative pathogens. Entasis plans to move multiple programs into mid- and late-stage clinical development, with an immediate focus on critical hospital infections. The company recently expanded its financing to support these development activities and broaden board expertise via investor appointees. Entasis Therapeutics is focused on the discovery and development of breakthrough anti-infective products targeted at serious and life-threatening bacterial infections. The company’s pipeline consists of first- and best-in-class clinical and preclinical-stage antibiotics for major Gram-negative infections. These candidates were discovered and are being developed using a unique, integrated discovery platform and strong clinical capabilities. Entasis says its programs target essential bacterial processes in a fundamentally novel way. The company plans to use the proceeds from the financing to advance its portfolio of innovative anti-infective products. Entasis is based in Waltham, Mass.

Total raised

$86M

Funding rounds

3

Latest round

Series B

Latest activity

Sep 2017